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Abstract 
 
 
Objective: The objective of this EBM review is to determine whether or not Crocus Sativus L. is 
as effective as Fluoxetine for the treatment of mild to moderate depression in adults aged 18-55.   
 
Study design: Systematic review of three English language, double-blind randomized controlled 
trials published between 2005-2007.  
 
Data source: Three double-blind randomized controlled trials published in peer-reviewed 
journals comparing the effectiveness of Crocus Sativus L. vs. Fluoxetine or placebo for the 
treatment of mild to moderate depression in adults were found using PubMed and Ebscohost.  
 
Outcomes measured: In all three articles the outcomes measured were improvement in 
depression symptoms based on 17-item Hamilton Depression rating scale.   
 
Results: Two studies that compared saffron to fluoxetine found that saffron was as effective as 
fluoxetine for the treatment of mild to moderate depression. One study that compared saffron to a 
placebo found that patients in the saffron group had a significant improvement in their symptoms 
compared to the placebo group.    
 
Conclusions: According to the three studies conducted, Saffron can be used as an alternative for 
the treatment of mild to moderate depression in adults.  
 
Keywords:  Crocus sativus; Saffron; Depression; Fluoxetine  
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INTRODUCTION 
Depression is a major problem in the United States, affecting about 5 percent of the 
adults.1 In fact, depression is one of the most common psychiatric conditions, and it is estimated 
that it will represent the second largest disease burden worldwide by the year 2020.1,2 American 
Psychiatric Association defines depression as a heterogeneous disorder often manifested with 
symptoms at the psychological, behavioral and physiological levels that is thought to result from 
biochemical changes in the brain.3 According to the Center for Disease Control (CDC), in 2003, 
national health expenditures for mental health services were estimated to be over 100 million 
dollars, and depression is estimated to cause 200 million lost workdays each year at a cost to 
employers of 17 to 44 billion dollars.4 There are many different medications available for the 
treatment of depression, including monoamine oxidase inhibitors (MAOIs), tricyclic 
antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine 
reuptake inhibitors (SNRIs) and many more. Although these medications can be very effective, 
there are many side effects associated with them.  Some side effects include anticholinergic 
affects, sexual dysfunction, cardiac arrhythmias, orthostatic hypotension, and many more. Also, 
about one-third of patients receive no benefit and one-third does not experience complete 
remission after monotherapy with antidepressants.2 
In the western society medications are the mainstay of treatment for depression, however 
in Persian countries herbs have been used for their antidepressants affects for thousands of years.  
Crocus Sativus, a very expensive spice also known as saffron has been used around the world for 
many years for its antidepressants effects. The major benefits of spices and natural herbs are that 
there are no side affects associated with them and they are relatively safe. Although this spice 
has been used around the world, especially in the Middle East for thousands of years there have 
 Noory, Saffron for Depression 2 
been no studies done to show its effectiveness.  In the recent years, researchers in Iran decided to 
test the effectiveness of this spice versus fluoxetine, a widely used SSRI for depression.  
OBJECTIVE 
The objective of this systematic review is to determine whether Crocus Sativus (saffron) 
is as effective as fluoxetine for the treatment of mild to moderate depression in adults aged 18-
55.  
METHODS 
Three double blind, randomized controlled studies were chosen for this review based on 
certain specific criteria. The population that was included in these studies was men and women 
between the ages of 18-55 with mild to moderate depression based on the Diagnostics and 
Statistical Manual of Mental Disorders (DSM-IV) criteria.  The intervention that was studied was 
the spice crocus sativus, more commonly known as saffron for the treatment of mild to moderate 
depression in these patients. Two of the articles compared saffron to the drug fluoxetine, a 
classic SSRI used to treat depression. One article compared saffron to placebo in order to study 
the effectiveness of the spice on these patients. The symptoms and severity of disease of the 
subjects were recorded at the beginning of the study using the Hamilton Depression rating scale 
(17-item HAM-D scale) and periodically throughout the study. All studies measured the 
improvement of depression symptoms using the same scale.  
Some keywords used in the search for RCT’s included depression, crocus sativus, 
saffron, and fluoxetine.  The chosen articles were all written in English and published in peer-
reviewed journals between 2005 and 2007. The articles were found using PubMed and 
EBSCOHOST databases, and chosen based on their relevance to the clinical question and for 
their emphasis on patient-oriented evidence based medicine. The inclusion criteria consisted of 
 Noory, Saffron for Depression 3 
males and females between the ages of 18-55 with mild to moderate depression with a baseline 
HAM-D 17 item score of at least 18 and ≤ 25. Exclusion criteria consisted of anyone under the 
age of 18 and over the age of 55, anyone with current cognitive disorder in the last year, or 
anyone with current or past history of bipolar disease, schizophrenia, schizotypal personality 
disorder, and/or borderline personality disorder.  Patients who scored greater than 2 on the 
suicide item of the HAM-D scale, and those with suicidal ideation were excluded as well. 
Pregnant women, or women of child-bearing age not on accepted form of birth control were also 
excluded (Table 1).  In the Basti et el. study the statistical data reported were P-value, RBI, ABI, 
and NNT. In Noorbala and Moshiri studies only a P-value was reported.  
 
Table 1- demographics and characteristics of included studies 
Study Type #Pts Age (yrs) Inclusion 
criteria 
Exclusion criteria W/D Interventions 
Basti 
(2007) 
Double 
blind 
RCT 
40  18-55 Pts who met 
the DSM-IV 
criteria for 
major 
depression. 
pts have a 
baseline 
HAM-D 17 
item score 
of at least 
18 and ≤ 25.  
Current cognitive disorder in 
the last year, current/past 
history of bipolar disease, 
schizophrenia, schizotypal 
personality disorder and 
border line personality 
disorder.  
Excluded if pt posed a 
significant risk of suicide.  
Pregnant woman or woman 
not using medically approved 
method of birth control were 
excluded. 
2  C. Sativus 15 
mg bid or 
fluoxetine 10 
mg bid.  
Moshiri   
(2006)  
Double 
blind 
RCT 
40 18-55  Pts who 
met the 
DSM-IV 
criteria for 
major 
depression. 
pts have a 
baseline 
HAM-D 17 
item score 
of at least 
Current cognitive disorder in 
the last year, current/past 
history of bipolar disease, 
schizophrenia, schizotypal 
personality disorder and 
border line personality 
disorder.  
Excluded if pt posed a 
significant risk of suicide.  
Pregnant woman or woman 
not using medically approved 
4 C. Sativus 
30mg/day or 
Placebo 
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OUTCOMES MEASURED 
 All three studies measured the improvement of depression symptoms using the Hamilton 
Depression scale.  In all three of the studies, all patients had a baseline psychiatric evaluation, a 
structured diagnostic interview and a medical history. Patients were randomized to receive either 
a capsule of C. sativus or fluoxetine in two of the studies, and a placebo pill in the third study. 
The patients were then followed and evaluated by a psychiatrist after 1, 2, 4, 6, and 8 weeks in 
one study1 and 1, 2, 4, and 6 weeks in the other two studies.2,3 The principle measure of the 
outcome was the 17-item HAM-D scale; the mean decrease in HAM-D score from baseline was 
used as the main outcome measure of response of depression to treatment.1,2,3   
RESULTS 
 In the study done by Basti et el, forty adult patients with major depression that scored at 
least 18 and ≤ 25 on the HAM-D depression scale participated in the trial. These 40 individuals 
were randomly assigned into two groups, 20 of them received fluoxetine 10 mg bid, and the 
remaining 20 received C. Sativus capsule 15 mg bid.  No significant differences were identified 
between the two groups in regards to patient demographics, age and gender. There were 2 
18 method of birth control were 
excluded.  
Noorbala 
(2005) 
Double 
blind 
RCT 
40 18-55 Pts who met 
the DSM-IV 
criteria for 
major 
depression. 
pts have a 
baseline 
HAM-D 17 
item score 
of at least 
18 
Current cognitive disorder in 
the last year, current/past 
history of bipolar disease, 
schizophrenia, schizotypal 
personality disorder and 
border line personality 
disorder.  
Excluded if pt posed a 
significant risk of suicide.  
Pregnant woman or woman 
not using medically approved 
method of birth control were 
excluded. 
2 C. Sativus 
30mg/day or 
Fluoxetine 20 
mg/day  
 Noory, Saffron for Depression 5 
withdraws, one from each group, thus 38 people completed the trial.  The outcomes were 
presented as dichotomous data and intention to treat analysis was used with last observation 
carried forward. The Hamilton Depression Rating Scale was used to compare the two groups, 
and there were no significant differences in the HAM-D scale between the two groups in week 0, 
the baseline evaluation (t=0.86, d.f=38, P=0.39).  In this study the percentage of responder was 
determined as 50% drop in the Hamilton Depression Rating Scale Score. Outcome measured was 
the mean decrease in HAM-D score from baseline as the measure of response of depression to 
treatment, so this negative value means that for every 10 patients that took crocus sativus there 
was one fewer 50% mean decrease from baseline in HAM-D score compared to fluoxetine.  
There were no significant differences between two treatments in terms of the percentage of 
responders, which is defined as at least 50% drop in the Hamilton Depression Rating Scale; 
fluoxetine 85% and Crocus Sativus 75% (Table 2). The data was not statistically significant 
(P=0.30). The relative benefit increase was calculated ot be -0.118, the absolute benefit increase 
was found to be -0.1, and the numbers needed to treat was calculated to be -10 (Table 2).  Thus, 
this study found no significant differences on the change of scores of the Hamilton Depression 
Rating Scale at week 8 compared to baseline in the two groups, meaning Crocus Sativus is as 
effective as fluoxetine in the treatment of mild or moderate depression. Ten side effects were 
observed over the 8 week study, including anxiety, decreased appetite, increased apetite, sexual 
dysfunction, tremor, nausea, headache, sweating, heart pounding, and insomnia. However, the 
difference between the crocus sativus and fluoxetine in the frequency of side effects was no 
significant.1 
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Table 2: Efficacy of Saffron vs. Fluoxetine  
Study Percentage 
of 
responders 
in 
Fluoxetine 
group 
Percentage 
of 
responders 
in Crocus 
sativus 
group.  
P-value RBI ABI NNT 
Basti et el 85% 75% P = 0.30 -0.118 -0.1 -10 
RBI = relative benefit increase, ABI= Absolute benefit increase 
NNT = Numbers needed to treat  
Noorbala et el study was a 6 week randomized and double-blind clinical trial that 
compared the effectiveness of crocus sativus to fluoxetine for the treatment of mild to moderate 
depression in adults. Forty outpatient adults who me the criteria for mild to moderate depression 
with a baseline HAM-D scale score of at least 18 participated in this study. Patients were 
randomly divided into two groups, one group received capsule saffron 30mg/day, and the other 
group received fluoxetine 20mg/day. The patients were assessed by a psychiatrist at baseline, 
and then at 1, 2, 4, and 6 weeks after the medication was started. The data in this study was 
continuous, and to compare the two groups at baseline and the outcome of two groups at the end 
of the trial, an unpaired Student’s t-test with a two-sided P-value was used. Differences were 
considered significant with P<0.05. In the fluoxetine group the drop in the HAM-D scale score at 
the end of week 6 compared to baseline was -15.00 ± 5.88, and in the saffron group it was -12.20 
± 4.67 (Table 3). The P value was calculated as 0.10, thus no significant differences was 
observed on the change of scores of the HAM-D scale at week 6 compared to baseline in the two 
groups (Table 3).  Over the course of the study nine side effects were observed, including 
anxiety, decreased appetite, increased appetite, sedation, nausea, headache, sexual dysfunction, 
tremor, and sweating. Although patients in the saffron groups reported slightly less side effects 
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compared to the fluoxetine group, there were no significant differences between the side effects 
in the two groups based on the p-values (table 4).3 
 
Table 3- Efficacy of Saffron vs. fluoxetine  
Study Drop in HAM-D 
score in fluoxetine 
group 
Drop in HAM-D 
score in saffron 
group 
P- Value 
Noorbala et el.  -15.00 ± 5.88 
 
-12.20 ± 4.67 0.10  
 
Table 4: Side effects of saffron vs. fluoxetine 
 
Side Effects Saffron Fluoxetine P-value 
Anxiety 3 6 0.45 
Decreased appetite  2 5 0.40 
Increased appetite 5 2 0.40 
Sedation 1 0 1.00 
Nausea 2 4 0.66 
Headache 3 6 0.45 
Sexual dysfuction 0 4 0.10 
Tremor 0 4 0.10 
Sweating 0 3 0.23 
 
Moshiri et el. study was a 6 week randomized and double-blind clinical trial that was 
conducted in the outpatient clinic of Roozbeh Psychiatric. Forty adult patients that met the DSM 
IV criteria for mild to moderate depression and had a baseline HAM-D scale score of at least 18 
participated in this study. The patients were randomly assigned into two groups: saffron and 
placebo. The saffron group received capsule petal of C. sativus 30mg/day and the placebo group 
received a placebo capsule. The A psychiatrist assessed the patients at baseline and after 1, 2, 4, 
and 6 weeks after the medication started. Throughout the study, the person who administered the 
medications, rater and patients were blind to assignments.  The data was continuous and an 
unpaired student’s t-test with a two-sided P-value was used to compare the two groups at 
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baseline and at the end of the trial. Results were presented as mean ± S.E.M. Differences were 
considered significant with P<0.05.  The changes in the HAM-D scale score at the endpoint 
compared to the baseline were found to be -14.01 ± 5.53 in the crocus sativus group and -5.05 ± 
4.63 in the placebo group (Table 5). The p-value was found to be P<0.0001, thus a significant 
difference was observed on the change of scores of the Hamilton Depression Rating Scale at 
week 6 compared to baseline in the two groups (Table 5).  There were eight side effects observed 
over the course of the 6-week trial, including anxiety, decreased appetite, stomach pain, tremor, 
nausea, headache, sweating and heart pounding. However, there was no significant difference 
between the frequency of side effects between the two groups.2   
Table 5- Efficacy of crocus sativus vs. placebo 
Study Crocus sativus Placebo P value 
Moshiri et el.  -14.01 ± 5.53 -5.05 ± 4.63 P <0.0001 
 
DISCUSSION 
 Some type of limitation exists in almost any study that is conducted.  Some limitations of 
these saffron studies include: age limitations, lack of placebo group, using a fixed dose of 
saffron, small number of participants, and short period of follow up. All three studies consisted 
of adults aged 18-55, however, depression is very common in the elderly and these studies do not 
include them. About 6 million Americans age 65 and older are affected with depression and 
saffron could be a good alternative treatment for them, however the safety and efficacy of it has 
not been studied in this age group.6 The studies all consisted of either 6-week or 8-week trial and 
that is not sufficient time to asses the effectiveness of a medication for depression, therefore a 
longer period of study is warranted to fully asses the effectiveness and safety of crocus sativus 
for treatment of depression. A fixed dose of saffron was used in all three studies and the dosage 
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that was used may not be as effective as a higher dose, or a lower dose may have fewer side 
effects, however, these questions cannot be answered unless another study is done with differing 
doses of saffron. Out of the three studies, only one contained a placebo group while the other two 
did not. All three studies were conducted in Iran, and about 96% of world’s saffron is supplied 
by Iran, and thus it is possible that there was a form of bias was present during the study.7 Due to 
these limitations that are present in the current studies done, many more studies are warranted to 
be conducted in order to fully asses the effectiveness and safety of saffron for the treatment of 
mild to moderate depression.  
CONLCUSION 
  In conclusion, three double-blind randomized controlled trials were evaluated in order to 
answer the question whether or not crocus sativus (saffron) is as effectives as fluoxetine for the 
treatment of mild to moderate depression in adults aged 18-55. Two of the studies compared the 
effectiveness and safety of saffron to fluoxetine, while one study compared it to a placebo. Both 
studies that compared the effectiveness of saffron concluded that it was as effective as fluoxetine 
for the treatment of depression in adults aged 18-55.  In the study conducted by Moshiri et el. 
where saffron was compared to a placebo, it was concluded that patients that received C. sativus 
experienced statistically significant benefits in their mood after 6 weeks of treatment compared 
to placebo.2 However, due to the limitations of age, small number of participants, fixed dose of 
saffron used, and lack of placebo group, many more studies are indicated before saffron can be 
used as a treatment for depression.  
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